155 related articles for article (PubMed ID: 22310967)
1. Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema.
Umegaki N; Kira M; Horiuchi T; Itoi S; Tani M; Yokomi A; Tanemura A; Miyahara H; Hatanaka M; Kitamura H; Kitano E; Katayama I
Mod Rheumatol; 2012 Nov; 22(6):928-30. PubMed ID: 22310967
[TBL] [Abstract][Full Text] [Related]
2. Successful use of etanercept in acquired angioedema in a patient with psoriatic arthritis.
Rottem M; Mader R
J Rheumatol; 2010 Jan; 37(1):209. PubMed ID: 20040647
[No Abstract] [Full Text] [Related]
3. Efficacy of etanercept in lymphedema associated with psoriatic arthritis.
Lekpa FK; Economu-Dubosc A; Fevre C; Claudepierre P; Chevalier X
J Rheumatol; 2009 Jan; 36(1):207-8. PubMed ID: 19208540
[No Abstract] [Full Text] [Related]
4. Etanercept in the treatment of severe, resistant psoriatic arthritis: continued efficacy and changing patterns of use after two years.
Yazici Y; Erkan D; Lockshin MD
Clin Exp Rheumatol; 2002; 20(1):115. PubMed ID: 11892697
[No Abstract] [Full Text] [Related]
5. Health-related quality of life and disability in patients with rheumatoid, early rheumatoid and early psoriatic arthritis treated with etanercept.
Picchianti-Diamanti A; Germano V; Ferlito C; Migliore A; D'Amelio R; Laganà B
Qual Life Res; 2010 Aug; 19(6):821-6. PubMed ID: 20373036
[TBL] [Abstract][Full Text] [Related]
6. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.
Prinz JC; Fitzgerald O; Boggs RI; Foehl J; Robertson D; Pedersen R; Molta CT; Freundlich B
J Eur Acad Dermatol Venereol; 2011 May; 25(5):559-64. PubMed ID: 20840349
[TBL] [Abstract][Full Text] [Related]
7. Psoriatic arthritis patients doing better on infliximab than etanercept.
Smith N; Gadsby K; Deighton C
Rheumatology (Oxford); 2007 Apr; 46(4):721-2. PubMed ID: 17314216
[No Abstract] [Full Text] [Related]
8. Etanercept: a new era in the treatment of psoriatic arthritis.
Mease PJ
Am J Manag Care; 2002 Apr; 8(6 Suppl):S181-93. PubMed ID: 11990863
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis.
Kowalzick L; Bertolini J; Baumann C; Walther B; Truhm B; Eickenscheidt L
J Dtsch Dermatol Ges; 2013 May; 11(5):447-9. PubMed ID: 23343137
[No Abstract] [Full Text] [Related]
10. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept.
Lubrano E; Spadaro A; Marchesoni A; Olivieri I; Scarpa R; D'Angelo S; Salvarani C; Mathieu A; Cauli A; Ferrara N; Helliwell P
Clin Exp Rheumatol; 2011; 29(1):80-4. PubMed ID: 21345296
[TBL] [Abstract][Full Text] [Related]
11. From wheels to feet: a dramatic response of severe chronic psoriatic arthritis to etanercept.
ElKayam O; Yaron M; Caspi D
Ann Rheum Dis; 2000 Oct; 59(10):839. PubMed ID: 11203155
[No Abstract] [Full Text] [Related]
12. One million U.S. adults may suffer from psoriatic arthritis.
Dermatol Nurs; 2002 Jun; 14(3):207-8. PubMed ID: 12099074
[No Abstract] [Full Text] [Related]
13. No evidence-based practice by biased information from systematic reviews: the case of etanercept and infliximab for the treatment of psoriatic arthritis.
Corrao S; Puleo A; Pistone G; Calvo L; Scaglione R; Licata G
Clin Exp Rheumatol; 2008; 26(1):164; author reply 165. PubMed ID: 18328174
[No Abstract] [Full Text] [Related]
14. Etanercept (Enbrel) -- an update.
Goffe B
Skin Therapy Lett; 2004 Dec-2005 Jan; 9(10):1-4, 9. PubMed ID: 15657632
[TBL] [Abstract][Full Text] [Related]
15. Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist.
Wong VK; Lebwohl MG
Expert Opin Biol Ther; 2005 Nov; 5(11):1505-13. PubMed ID: 16255653
[TBL] [Abstract][Full Text] [Related]
16. Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept.
Fiocco U; Ferro F; Vezzù M; Cozzi L; Checchetto C; Sfriso P; Botsios C; Ciprian L; Armellin G; Nardacchione R; Piccoli A; Todesco S; Rubaltelli L
Ann Rheum Dis; 2005 Jun; 64(6):899-905. PubMed ID: 15567814
[TBL] [Abstract][Full Text] [Related]
17. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.
Strand V; Sharp V; Koenig AS; Park G; Shi Y; Wang B; Zack DJ; Fiorentino D
Ann Rheum Dis; 2012 Jul; 71(7):1143-50. PubMed ID: 22258482
[TBL] [Abstract][Full Text] [Related]
18. Psoriatic onychopachydermoperiostitis: improvement with etanercept.
Dans M; Hivnor C; van Voorhees AS
Br J Dermatol; 2005 Oct; 153(4):858-9. PubMed ID: 16181482
[No Abstract] [Full Text] [Related]
19. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
Antoni C; Manger B
Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
[TBL] [Abstract][Full Text] [Related]
20. In etanercept-treated psoriatic arthritis patients clinical improvement correlated with an increase of serum cortisol relative to other adrenal hormones.
Atzeni F; Sarzi-Puttini P; DePortu S; Cutolo M; Carrabba M; Straub RH
Clin Exp Rheumatol; 2008; 26(1):103-8. PubMed ID: 18328154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
